Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Auteurs : Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart M, Michiels S, Bradbury I, Sotiriou C, Loi S
Année : 2015
Journal : JAMA Oncol
Volume : 1(4)
Pages : 448-54

Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer.

Auteurs : Zardavas D, Piccart-Gebhart M
Année : 2015
Journal : Am Soc Clin Oncol Educ Book
Volume : 35
Pages : e183-90

Tailoring therapies - improving the management of early breast cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Auteurs : Coates AS, Winer EP, Goldhirsch A, Gelber Rd, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1533-46

Clinical management of breast cancer heterogeneity.

Auteurs : Zardavas D, Irrthum A, Swanton C, Piccart-Gebhart M
Année : 2015
Journal : Nat Rev Clin Oncol
Volume : 12(7)
Pages : 381-94

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Auteurs : Strasser-Weippl K, Horick N, Smith IE, O Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Année : 2015
Journal : Breast Cancer Res
Volume : 17(1)
Pages : 56

Uncovering the genomic heterogeneity of multifocal breast cancer.

Auteurs : Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S, Gundem G, Rothé F, Majjaj S, Garuti A, Carminati E, Loi S, Van Brussel T, Boeckx B, Maetens M, Mudie L, Vincent D, Kheddoumi N, Serra L, Massa I, Ballestrero A, Amadori D, Salgado R, de Wind A, Lambrechts D, Piccart-Gebhart M, Larsimont D, Campbell PJ, Sotiriou C
Année : 2015
Journal : J. Pathol.
Volume : 236(4)
Pages : 457-66

New approaches for improving outcomes in breast cancer in Europe.

Auteurs : Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart-Gebhart M
Année : 2015
Journal : Breast
Volume : 24(4)
Pages : 321-330

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Auteurs : Boyle FM, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein D
Année : 2015
Journal : Eur. J. Cancer
Volume : 51(6)
Pages : 685-96

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart-Gebhart M, Van Laethem JL, Flamen P
Année : 2015
Journal : BMC Cancer
Volume : 15
Pages : 173

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.

Auteurs : Azim HA, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart-Gebhart M, Dougall WC, Pruneri G, Sotiriou C
Année : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 24

Adjuvant systemic therapy in breast cancer: quo vadis?

Auteurs : Sonnenblick A, Piccart-Gebhart M
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1629-34

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Auteurs : Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart-Gebhart M, Baselga J
Année : 2015
Journal : Clin Cancer Res
Volume : 21(3)
Pages : 569-76

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

Auteurs : Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(12)
Pages : 1334-9

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.

Auteurs : Stahel R, Bogaerts J, Ciardiello F, De Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart-Gebhart M, Smit E, Sotiriou C, Tejpar S, van Cutsem E, Tabernero J
Année : 2015
Journal : Cancer Treat Rev
Volume : 41(2)
Pages : 129-135

The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?

Auteurs : Piccart-Gebhart M
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(4)
Pages : 347-54

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Auteurs : McCullough AE, + collaborators (among others :, Piccart-Gebhart M, Viale G
Année : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 485-92

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Auteurs : Viale G, Slaets L, Bogaerts J, Rutgers E, + collaborators (among others :, Piccart-Gebhart M, Cardoso F
Année : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 816-23

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Auteurs : Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart-Gebhart M, Rugo H, Sledge G, Thomssen C, + collaborators (among others :, Winer A
Année : 2014
Journal : Breast
Volume : 23(5)
Pages : 489-502

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Auteurs : Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart-Gebhart M, Rugo H, Sledge G, Thomssen C
Année : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1871-88

Words matter: distinguishing personalized medicine" and "biologically personalized therapeutics"."

Auteurs : Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, Piccart-Gebhart M, Sidransky D, Soussan-Gutman L, Tziraki C
Année : 2014
Journal : J. Natl. Cancer Inst.
Volume : 106(12)